Kiromic BioPharma Reports Favorable Safety, Tolerability, an

Trial’s Safety Monitoring Committee Recommends Maintaining Initial Cell Dose Level for Next Cohort of Patients

...

Related Keywords

Beverly Hills , Texas , United States , Houston , Kiromic Biopharma , Pietro Bersani , Company Deltacel , Twitter , Kiromic Biopharma Inc , Beverly Hills Cancer Center , Securities Exchange , Safety Monitoring Committee , Linkedin , Gamma Deltat Cell , Monitoring Committee , Chief Executive Officer , Gamma Deltat Cell Infusions , Subjects With Stage , Non Small Cell Lung , Hills Cancer Center , Gamma Deltat Cells , Securities Exchange Act , Annual Report , Markets ,